An anti-fibrotic microRNA, AFM-1000, for the therapy of pulmonary fibrosis
- Summary
- This invention includes ananti-fibrotic therapy that effectively reduces pulmonary fibrosis. In an in vitro fibroblast culture system, an in vivo bleomycin-induced pulmonaryfibrosis in mice and lung tissues from IPF patients, it was discovered that theexpression of a number of microRNAs were down-regulated in all three models.Adenovirus-mediated expression of a specific down regulated microRNA attenuatedlung fibrosis and improved lung function in a bleomycin mouse model. Theseresults suggested that upregulating this microRNA may be a potentialtherapeutic for IPF.
- Technology Benefits
- Anti-fibrotic therapyTargets multiple pathwaysAttenuates fibrosis in mouse model
- Technology Application
- Therapeutic forpulmonary fibrosisTherapeutic forother fibrotic diseases
- Detailed Technology Description
- None
- *Abstract
-
None
- *Background
- Idiopathic pulmonary fibrosis (IPF) isa fatal fibrotic lung disease characterized by a progressive decline in lungfunction that is chronic and fatal. The only treatment option shown tosignificantly extend life in a patient with IPF is a lung transplant, which onlyprovides a ~40% survival rate 5 years post-operation. IPF usually occurs inpeople between the ages of 50 and 70, affecting approximately 200,000 individualsand causing 40,000 annually in America each year. Unfortunately, no effectivetherapeutic has been developed to halt, or reverse IPF.
- *Stage of Development
- Proof of concept.
- Country/Region
- USA
For more information, please click Here
